Overview
Choose your reading level:
In plain language
Desmopressin is a lab-made version of vasopressin, the natural hormone that helps your kidneys hold on to water. It is 9 amino acids long.
It is used to treat a condition where the body makes too little vasopressin and people pass large amounts of urine, for bedwetting in children, and for waking at night to urinate. It also helps some people with mild bleeding disorders. The main risk is low blood sodium if people drink too much fluid while taking it.
For students
Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) is a nonapeptide of about 1,069 Da. Two changes from vasopressin, removing the N-terminal amine and replacing L-Arg8 with D-Arg, make it longer-acting and highly selective for the kidney V2 receptor, with little vasoconstricting V1a activity.
V2 activation inserts aquaporin-2 channels into collecting duct cells, concentrating urine. Desmopressin also releases von Willebrand factor and factor VIII from endothelial stores, which is why it is used in mild hemophilia A and type 1 von Willebrand disease.
For researchers and instructors
Indications. Central diabetes insipidus (now often called arginine vasopressin deficiency), primary nocturnal enuresis, nocturia due to nocturnal polyuria (specific low-dose products) and bleeding disorders. Available as injection, nasal spray and tablets.
Safety. Hyponatremia is the major risk, especially in older adults; nocturia products carry a boxed warning. Fluid restriction and sodium monitoring are standard.
Pharmacology. Tachyphylaxis of the hemostatic response occurs after repeated doses as endothelial stores deplete.
Status. FDA-approved, with multiple formulations.
Molecular identity
- Amino acids
- 9
- Molecular weight
- ~1,069.2 Da
- Formula
- C₄₆H₆₄N₁₄O₁₂S₂
- Sequence
- Mpa–Tyr–Phe–Gln–Asn–Cys–Pro–D-Arg–Gly–NH₂ (disulfide)
Origin and history
Desmopressin was created in 1967 by Milan Zaoral and colleagues at the Czechoslovak Academy of Sciences in Prague. They removed vasopressin’s starting amino group and swapped in a D-arginine, making a molecule that keeps the water-retaining effect without raising blood pressure.
Developed by Ferring, it was approved in the U.S. in 1978. In 1977 Pier Mannucci in Milan showed it also raises clotting factors, so it is used for mild hemophilia A and von Willebrand disease.
Key people
- Milan ZaoralCzechoslovak Academy of Sciences
- Pier MannucciDiscovered its clotting use
Timeline
- 1967
Desmopressin synthesized
- 1977
Use in bleeding disorders shown
- 1978
Approved in the U.S.
See every peptide on one history timeline.
Human evidence
Approved for central diabetes insipidus, bedwetting and some bleeding disorders such as mild hemophilia A and von Willebrand disease.
Registration and enrollment are not proof of benefit; check study results directly.
Explore original publications and distinguish preclinical findings from controlled human evidence.
Safety and regulatory status
See every compound on the regulatory tracker.
FDA-approved. The main risk is low blood sodium (hyponatremia).
This profile is educational and does not provide treatment, dosing or sourcing guidance.
Sources
- PubMed literature search: Desmopressin
- PubChem compound search: Desmopressin
- DailyMed (FDA label search): Desmopressin
- PubMed: Mannucci 1977 desmopressin
- ClinicalTrials.gov search: Desmopressin
Hernandez Gener, E. (2026, November 7). Desmopressin: molecular data, research history and evidence. VALREXA Biosciences. https://valrexa.com/peptides/desmopressin.html
APA style · Last reviewed November 7, 2026 · Our editorial standardsLast reviewed November 7, 2026. Trial and regulatory status can change; confirm in the linked registries. This profile is educational and is not medical advice, a treatment recommendation, or dosing or sourcing guidance. Report an error · Corrections policy